Answers are grounded in this paper and cite their sources.
SARS-CoV-2 poses a significant risk to global healthcare systems based on the recent worldwide COVID-19 pandemic. Spike proteins are the hallmark of SARS-Cov-2, which bind to ACE2 receptors that lead to cell and membrane fusion. To address and alleviate respiratory health issues, we at Shiban Pharma have developed a range of natural products derived from plant and herb extracts, recognized for their antiviral activity against SARS-CoV-2, such as propolis extracts. In this study, we are evaluating the effects of the immuno-formula Shiban 2 and Shiban 5 (IF 2/5) on the infection of airway epithelial cells (A549) and primary airway epithelial cell (PAEC) by SARS-CoV-2. The objective is to evaluate the effects of IF 2/5 and of a placebo on viral infection. Our in vitro data demonstrates that IF 2/5 inhibits SARS-CoV-2 replication in a dose-dependent manner. Moreover, the compounds in IF 2/5 exhibit synergy, as determined by the Bliss method and Bliss synergy score. The Bliss synergy model was applied to explore the interaction between Propolis and Tannic Acid in modulating SARS-CoV-2 infection inhibition. Finally, our IF 2/5 also displays anti-inflammatory effects on cytokine markers IL-17A, IL-17F, and IL-8, contributing to an antiviral immunomodulatory response in the Propolis and Tannic Acid combination in vitro.
No takes yet. Share an insight, caveat, or question.
Shaibani et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: